scholarly journals HPV Vaccines: Myths and Facts

2020 ◽  
Author(s):  
Mehmet Faruk Kose ◽  
Emine Karabuk
Keyword(s):  
Hpv Vaccines

Development of Human Papillomavirus (HPV) Vaccines: A Review of Literature and Clinical Update

2016 ◽  
Vol 11 (4) ◽  
pp. 284-289 ◽  
Author(s):  
Vikrant Chadrakant Sangar ◽  
Balasaheb Ghongane ◽  
Gaurav Mathur
Keyword(s):  
Human Papillomavirus ◽  
Review Of Literature ◽  
Hpv Vaccines

scholarly journals Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis

2020 ◽  
Author(s):  
Sedigheh Taghinezhad-S ◽  
Hossein Keyvani ◽  
Luis G. Bermúdez-Humarán ◽  
Gilbert G. G. Donders ◽  
Xiangsheng Fu ◽  
...  
Keyword(s):  
Lactic Acid ◽  
Lactic Acid Bacteria ◽  
Genetically Modified ◽  
Hpv Vaccines

scholarly journals The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection—A Systematic Review

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1339
Author(s):  
Kristoffer Juul Nielsen ◽  
Kathrine Kronberg Jakobsen ◽  
Jakob Schmidt Jensen ◽  
Christian Grønhøj ◽  
Christian Von Buchwald
Keyword(s):  
Cohort Study ◽  
Oropharyngeal Cancer ◽  
Hpv Infection ◽  
Case Control ◽  
Igg Antibodies ◽  
Hpv Vaccines ◽  
Case Control Studies ◽  
Cross Sectional ◽  
Post Vaccination ◽  
Cross Sectional Studies

Human papillomavirus (HPV) imposes an increased risk of developing cervical, anal and oropharyngeal cancer. In the Western world, HPV infection is currently the major cause of oropharyngeal cancer. The effectiveness of HPV vaccines for oral or oropharyngeal HPV infection is yet to be determined. This study conducted a systematic literature search in Pubmed and Embase. Studies investigating the impact of HPV vaccines on oral or oropharyngeal HPV infection were enrolled. This review reports the relative prevention percentage (RPP), including a risk of bias assessment as well as a quality assessment study. Nine studies were included (48,777 participants): five cross-sectional studies; one randomized community trial study (RCT); one longitudinal cohort study; and two case-control studies. A significant mean RPP of 83.9% (66.6–97.8%) was calculated from the cross-sectional studies, 82.4% in the included RCT and 83% in the longitudinal cohort study. Further, two case-control studies that measured antibody response in participants immunized with HPV vaccines were included. Respectively, 100% and 93.2% of participants developed HPV-16 Immunoglobulin G (IgG) antibodies in oral fluids post-vaccination. Analysis of the studies identified a significant decrease in vaccine-type oral or oropharyngeal HPV infections in study participants immunized with HPV vaccines across study designs and heterogenous populations. Further, a significant percentage of participants developed IgG antibodies in oral fluid post-vaccination.

scholarly journals Manufacturing costs of HPV vaccines for developing countries

Vaccine ◽  
2016 ◽  
Vol 34 (48) ◽  
pp. 5984-5989 ◽  
Author(s):  
Chaevia Clendinen ◽  
Yapei Zhang ◽  
Rebecca N. Warburton ◽  
Donald W. Light
Keyword(s):  
Developing Countries ◽  
Hpv Vaccines ◽  
Manufacturing Costs

HPV vaccines

2006 ◽  
Vol 20 (2) ◽  
pp. 279-293 ◽  
Author(s):  
Margaret Stanley
Keyword(s):  
Hpv Vaccines

scholarly journals RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates

2021 ◽  
Vol 10 (5) ◽  
pp. 1044
Author(s):  
Bettina Huber ◽  
Joshua Weiyuan Wang ◽  
Richard B. S. Roden ◽  
Reinhard Kirnbauer
Keyword(s):  
Small Animal ◽  
Good Manufacturing Practice ◽  
Special Focus ◽  
T Cell Epitopes ◽  
Hpv Vaccines ◽  
Structural Protein ◽  
Vaccine Candidates ◽  
Protective Antibodies ◽  
Minor Structural Protein ◽  
Hpv Types

Licensed human papillomavirus (HPV) vaccines contain virus-like particles (VLPs) self-assembled from L1 major-capsid proteins that are remarkably effective prophylactic immunogens. However, the induced type-restricted immune response limits coverage to the included vaccine types, and costly multiplex formulations, restrictive storage and distribution conditions drive the need for next generation HPV vaccines. Vaccine candidates based upon the minor structural protein L2 are particularly promising because conserved N-terminal epitopes induce broadly cross-type neutralizing and protective antibodies. Several strategies to increase the immunological potency of such epitopes are being investigated, including concatemeric multimers, fusion to toll-like receptors ligands or T cell epitopes, as well as immunodominant presentation by different nanoparticle or VLP structures. Several promising L2-based vaccine candidates have reached or will soon enter first-in-man clinical studies. RG1-VLP present the HPV16L2 amino-acid 17–36 conserved neutralization epitope “RG1” repetitively and closely spaced on an immunodominant surface loop of HPV16 L1-VLP and small animal immunizations provide cross-protection against challenge with all medically-significant high-risk and several low-risk HPV types. With a successful current good manufacturing practice (cGMP) campaign and this promising breadth of activity, even encompassing cross-neutralization of several cutaneous HPV types, RG1-VLP are ready for a first-in-human clinical study. This review aims to provide a general overview of these candidates with a special focus on the RG1-VLP vaccine and its road to the clinic.

scholarly journals HPV vaccines and cancer prevention, science versus activism

2013 ◽  
Vol 8 (1) ◽  
Author(s):  
Lucija Tomljenovic ◽  
Judy Wilyman ◽  
Eva Vanamee ◽  
Toni Bark ◽  
Christopher A Shaw
Keyword(s):  
Cancer Prevention ◽  
Prevention Science ◽  
Hpv Vaccines

scholarly journals Awareness and knowledge of Human Papillomavirus ( HPV ), HPV ‐related cancers, and HPV vaccines in an uninsured adult clinic population

2016 ◽  
Vol 5 (11) ◽  
pp. 3346-3352 ◽  
Author(s):  
Carmen Radecki Breitkopf ◽  
Lila J. Finney Rutten ◽  
Victoria Findley ◽  
Debra J. Jacobson ◽  
Patrick M. Wilson ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccines ◽  
Clinic Population
Sign in / Sign up

Export Citation Format

Share Document